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Summary It is now recognised that epithelial-stromal interactions are important in a wide range of disease
processes including neoplasia and inflammation. Metalloproteinases are central to matrix degradation and
remodelling, which are key events in tumour invasion and metastasis and may also be involved in tissue
changes occurring in chronic inflammation. Immunohistochemistry was performed on sections from 50 patients
with pancreatic cancer (n =27), ampullary cancer (n = 12), low bile duct cancer (n =3), neuroendocrine tumours
(n=3) and chronic pancreatitis (n = 5), using antibodies raised against collagenase (MMP2), stromelysin
(MMP3) and tissue inhibitor of metalloproteinase (TIMPI) and developed using the avidin-biotin complex
method.Abundance of MMP2, MMP3 and TIMPI was greater in pancreatic and ampullary cancer than any
other pathology and immunoreactivity in the malignant epithelial cells in pancreatic and ampullary cancer was
greater than in the stromal tissues (in pancreatic cancer: MMP2 100% vs 37%, MMP3 93% vs 15%, TIMPI
93% vs 4%, P<0.0001). There were strong correlations between the immunoreactivity of the two antibodies
for MMP2 (P<0.0001), between MMP2 and TIMPI (P<0.0001) and between MMP3 and TIMPI
(P<0.0001). The immunoreactivity for TIMPI in pancreatic and ampullary cancers with lymph node
metastases was significantly less compared with those cases without lymph node metastases (P< 0.02) and there
was an association between increased immunoreactivity for MMP2 and the degree of tumour differentiation
(P<0.01). The results implicate MMP2, MMP3 and TIMPI in the invasive phenotype of pancreatic and
ampullary cancer.
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Ductal adenocarcinoma of the pancreas is the fifth most
common cause of cancer death in the western world
(Haddock and Carter, 1990). Fewer than 10% of pancreatic
cancers are resectable at the time of presentation, and even
after resection the 5 year survival rate is only 10- 15%.
Periampullary cancers (arising from the ampulla of Vater or
lower bile duct) are much less common than pancreatic
cancer; they are often resectable and are associated with 5
year survival rates of 30% or more (Russell, 1990). The better
outcome from ampullary cancer may be related to earlier
presentation as survival for both types of cancer is strongly
correlated with tumour grade, local invasion and lymph node
metastasis (Neoptolemos et al., 1988; Yamaguchi and Enjoji,
1989).
The ability of malignant epithelial cells to break down
adjacent extracellular matrix (ECM) (Hart et al., 1989) is an
essential step in the processes of invasion and metastasis
(Liotta et al., 1980; Liotta and Stetler-Stevenson, 1991). Loss
of basement membrane integrity in breast and colorectal
cancers have been shown to be associated with an increased
risk of metastasis and poor prognosis (Charpin et al., 1986;
Forster et al., 1986). In pancreatic cancers discontinuous or
absent basement membrane type IV collagen is seen more
frequently than in benign disease (Lee et al., 1994), and
pancreatic cancer is characterised by aggressive local
behaviour, early metastasis and an intense desmoplastic
stromal reaction (Mollenhauer et al., 1987; Nagakawa et
al., 1989, 1992).
The matrix metalloproteinases (MMP) are a family of
proteolytic enzymes that are capable of degrading different
substrates within the ECM (Cottam and Rees, 1993) and play
a major role in the process of invasion and metastasis (Liotta
et al., 1991). The functional activity of the activated forms of
these enzymes appear to be controlled by three specific tissue
inhibitors of metalloproteinases (TIMPI, 2, 3) (Cottam and
Rees, 1993; Uria et al., 1994). The cellular source of MMPs is
often difficult to identify in complex tissues. MMP1 (type I
collagenase) appears to be a product of fibroblasts (Biswas,
1982), some tumour cell lines, including the pancreatic cancer
cell line SUIT2 (Taniguchi et al., 1992) and colonic tumours
(Gray et al., 1993). MMP9 (92 kDa type IV collagenase) is
also a product of some cancer cell lines (Okada et al., 1990,
1992; Shima et al., 1993), squamous cell carcinoma of the
skin (Pyke et al., 1992) and prostate adenocarcinoma (Hamdy
et al., 1994) but also localises to tumour-infiltrating mono-
nuclear cells, especially macrophages (Naylor et al., 1994).
MMP3 (stromelysin) cleaves collagen types III, IV, V and IX
and degrades gelatin, fibronectin, laminin, elastin and
proteoglycan link protein (Chin et al., 1985). MMP3 has
been shown to be produced by squamous cell carcinomas
(Ostrowski et al., 1988; Matrisian et al., 1991). MMP1O
(stromelysin 2) may be expressed in tumours with an
epidermoid component (Muller et al., 1988), whereas
MMP1 1 (stromelysin 3) is expressed in the stromal cells of
breast cancer (Basset et al., 1990) and in colorectal
malignancy (Urbanski et al., 1993). MMP7 (Pump-1) is a
smaller enzyme involved in uterine involution but also has a
putative role in colonic cancer development (Yoshimoto et
al., 1993) and is expressed by some colorectal line cells
(Miyazaki et al., 1990).
MMP2 (72 kDa type IV collagenase) activity is highly
correlated with the invasive/metastatic phenotype. It is
known to cleave basement membrane type IV collagen as
well as V, VII, X and degrades gelatin, fibronectin, elastin
and laminin (Murphy et al., 1991a,b). MMP2 has been shown
to be produced by fibroblasts (Overall et al., 1991),
endothelial cells (DeClerck et al., 1989; Unemori et al.,
1992) and human cancer cell lines (Brown et al., 1990; Zucker
et al., 1990; Agarwal et al., 1994) but in human colorectal,
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1995breast and skin carcinomas most of the mRNA is found to
localise to stromal fibroblasts (Poulsom et al., 1992, 1993).
This may be explained by cell-surface uptake by a putative
receptor and membrane activation by a novel membrane-
associated metalloproteinase (Sato et al., 1994).
Since TIMPI and TIMP2 bind stoichiometrically with the
activated form of the MMPs in a 1:1 ratio, small changes in
the level of these enzymes may lead to biologically significant
changes in proteolytic activity. TIMPI binds to the activated
forms of MMP1, MMP3 and MMP9 (Welgus and Stricklin,
1983; Welgus et al., 1985; Wilhelm et al., 1989), whereas
TIMP2 inhibits both pro-MMP2 and activated MMP2
(Stetler-Stevenson et al., 1990). Both TIMP1 and TIMP2
have been shown to be produced in cancer cell lines in vitro
(Stetler-Stevenson et al., 1990; Ponton et al., 1991) and the
epithelial component of human adenocarcinomas in vivo
(Hewitt et al., 1991; Poulsom et al., 1992, 1993).
Our understanding of the MMPs in malignancy is still
fragmented and their role in human pancreatic and ampullary
cancers specifically is almost unknown, although experi-
mental data have been reported for pancreatic cancer cell
lines, concerning MMPI and MMP2 (Moll et al., 1990;
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Zucker et al., 1992). The intense stromal reaction associated
with pancreatic cancer (Mollenhauer et al., 1987) and its
aggressive local invasive characteristics (Nagakawa et al.,
1992), suggest that MMPs may play a role in the invasive
phenotype of pancreatic cancer. This study reports the
localisation of the protein products for MMP2, MMP3 and




Four monoclonal murine antibodies were used that are
specific to the 72 kDa type IV collagenase (MMP2,
antibodies GL22 and GL8), stromelysin 1 (MMP3, antibody
Mac78) and the tissue inhibitor of the metalloproteinases
(TIMPI, antibody Macl5). These antibodies were raised
against recombinant enzymes and subsequently characterised
by Western blotting. They were compared with all members
of the MMP/TIMP family to confirm specificity and
absorption controls with recombinant enzymes performed
Table I Histopathology, stage and prognostically important factors of the sections used
Adenocarcinoma Ampullary Low bile duct Neuroendocrine
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<2 3 (11%) 5 (42%) 1 1
2-5 22b (82%) 4b (33%) 1 2
> 5 2 (7%) 1 (8%) 1 0
aPancreas cancers were better differentiated than ampullary cancers (P<0.004). bMore pancreas
cancers over 2cm than ampullary cancers (P<0.009).
Table H Epithelial cell staining with the different antibodies
Epithelial cell Adenocarcinoma Ampullary Low bile duct Neuroendocrine Chronic
Antibody staining pancreas adenocarcinoma adenocarcinoma tumours pancreatitis
GL22 72kDa Type IV Negative 0 0 0 2 0
collagenase (MMP2) Weak 4 (15%) 4 (33%) 2 1 2
Moderate 18 (67%) 5 (42%) 1 0 3
Strong 5 (18%) 3 (25%) 0 0 0
GL8 72kDa Type IV Negative 0 0 0 2 0
collagenase (MMP2) Weak 12 (44%) 1 (8%) 0 1 3
Moderate 14 (52%) 10 (83%) 3 0 2
Strong 1 (4%) 1 (8%) 0 0 0
Mac 78 Stromelysin 1 (MMP3) Negative 2 (7%) 1 (8%) 1 1 0
Weak 11 (41%) 5 (42%) 0 1 2
Moderate 8 (30%) 3 (25%) 1 1 2
Strong 5 (18%) 3 (25%) 1 0 1
Mac 15 Tissue inhibitor of Negative 2 (7%) 0 0 1 0
metalloproteinase (TIMPI) Weak 21 (78%) 8 (67%) 2 2 4
Moderate 4 (15%) 4 (33%) 1 0 1
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previously in our laboratories showed extinction of
immunoreactivity (Afzal et al., 1995). The antibodies were
provided by the research and development section of Celltech
UK and are not commercially available.
Tissue sections
All sections were part of the archival tissue collection of the
Department of Histopathology, Royal Postgraduate Medical
School, Hammersmith Hospital. All tissues had been fixed in
10% formalin and mounted in paraffin blocks from which
4 jgm tissue sections were taken on to poly-L-lysine coated
slides.
The murine avidin-biotin complex method was used for
antigen detection with antibody dilutions of 1:100 for GL8
(stock solution 1.57 mg ml-' IgG), 1:40 for GL22 (stock
solution 2.77 mg ml-' IgG), 1:40 for Mac78 (stock solution
2.88 mg ml-' IgG) and 1:25 for MaciS (stock solution
1.75 mg ml-' IgG). Sections were dewaxed and rehydrated
through ethanol, endogenous peroxidase was blocked with
hydrogen peroxide and non-specific protein binding was
reduced using goat serum. The primary antibody was applied
at the correct dilution in a volume of 50-100 Ml and left
overnight at 4°C. The primary antibody was removed and the
sections washed in phosphate-buffered saline (PBS), biotiny-
lated anti-murine goat antibody at a dilution of 1: 500 was
applied to each section and left for 1 h (Dako, High
Wycombe, UK). The sections were washed in PBS and
streptavidin-labelled peroxidase at a dilution of 1: 500 was
applied to the sections and left for 1 h (Dako). The sections
were then washed for a third time in PBS and developed in
500 ml of 0.01% PBS, 0.025%, 3.3'-diaminobenzidine
tetrahydrochloride (Sigma, Poole, UK) and 500 jl of 30%
hydrogen peroxide. The sections were washed again in PBS,
counterstained using haematoxylin, dehydrated through
alcohol and mounted in Pertex (Cellpath, UK).
Specificity of immunostaining was established using a
negative control for each section, missing out the primary
antibody and using 100 Ml of the diluent alone. Also included
in each batch of sections was a known positive control
previously validated within the laboratory by parallel in situ
hybridisation and/or enzymology.
Sections were taken from 50 individual patients: 27 with
ductal adenocarcinoma of the pancreas, 12 with ampullary
cancer, three with lower bile duct cancer, three with
neuroendocrine pancreatic tumours and five with chronic
pancreatitis (Table I). All sections were stained with each
antibody and scored independently by two individuals
(GWHS, SRB) for intensity of staining of epithelial, stromal
and normal tissue. Data were collected using the following
scoring system: negative, 0; weak, 1/2; moderate, 3/4; strong,
5/6. The results were compared with TNM staging, tumour
grade and tumour size.
Statistical analysis
Statistical analysis was performed using the Pearson chi-
squared test, the chi-squared test for trend and for other data
using the Fisher's exact test where applicable (BMDP
Statistical Software package and InStat by Graphpad).
Results
The tumour and lymph node stage and tumour differentiation
and size are shown in Table I. The intensity of staining in
each tissue type with each antibody for epithelial, stromal
and adjacent normal cells are shown in Tables II and III.
Immunoreactivities for MMP2, MMP3 and TIMPI were
greatest in adenocarcinomas of pancreas and ampulla
compared with those in the other pathologies. None of the
neuroendocrine tumours stained more than weakly with any
Table III Stromal cell staining with the different antibodies
Stromal cell staining Adjacent normal cell staining
Antibody Intensity of Adenocarcinoma Ampullary Adenocarcinoma Ampullary
staining pancreas adenocarcinoma pancreas adenocarcinoma
GL22 72kDa Type IV collagenase Negative 17 (63%) 10 (83%) 23 (85%) 12 (100%)
(MMP2) Weak 7 (26%) 2 (17%) 3 (11%) 0
Moderate 3 (11%) 0 1 (4%) 0
Strong 0 0 0 0
GL8 72kDa Type IV collagenase Negative 16 (59%) 0 27 (100%) 12 (100%)
(MMP2) Weak 9 (33%) 7 (58%) 0 0
Moderate 2 (7%) 5 (42%) 0 0
Strong 0 0 0 0
Mac 78 Stromelysinl (MMP3) Negative 22 (81%) 8 (67%) 25 (93%) 10 (83%)
Weak 3 (11%) 2 (17%) 1 (4%) 1 (8%)
Moderate 1 (4%) 2 (17%) 0 1 (8%)
Strong 0 0 0 0
Mac 15 Tissue inhibitor or metallo- Negative 26 (96%) 10 (83%) 25 (93%) 8 (67%)
proteinase (TIMPI) Weak 1 (4%) 2 (17%) 2 (7%) 3 (25%)
Moderate 0 0 0 1 (8%)
Strong 0 0 0 0
Table IV Epithelial cell staining with the antibody to TIMPI in lymph node-positive and lymph node-negative
patients
Lymph node Intensity of epithelial cell staining with TIMP-1
status ofpatient Negative Weak Moderate Strong
Pancreas cancer Positive (n = 16) 1 (6%) 14 (88%) 1 (6%) 0
Negative (n = 11) 1 (9%) 7 (64%) 3 (27%) 0
Ampullary cancer Positive (n = 8) 0 7 (88%) 1 (12%) 0
Negative (n = 4) 0 1 (25%) 3 (75%) 0MMP2,3 and TIMP1 expression in pancreatic disease
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Table V Epithelial cell staining with the antibody to MMP2 (GL8) according to tumour differentiation
Tumour cell Intensity ofepithelial cell staining with MMP-2
differentiation Negative Weak Moderate Strong
Pancreas cancer Well (n = 11) 0 6* (55%) 5* (45%) 0
Moderate (n = 10) 0 5 (50%) 4 (40%) 1 (10%)
Poor (n = 6) 0 0* 6* (100%) 0
Ampullary cancer Well (n =2) 0 0 2 (100%) 0
Moderate (n = 3) 0 0 2 (67%) 1 (33%)
Poor (n = 7) 0 1 (14%) 6 (86%) 0
*P<0.01.
Figure 2 A poorly differentiated ductal adenocarcinoma of the
pancreas showing moderate to strong heterogeneous cytoplasmic
staining of the neoplastic cells for MMP3 (Mac 78). Weak
staining of desmoplastic fibroblasts is also noted (ABC-
immunoperoxidase, original magnification x 250).
Figure 1 A poorly differentiated ampullary adenocarcinoma
invading around unstained benign tubular glands (with polarised
nuclei). The tubules and single cells of the carcinoma show
moderately intense staining by MMP3 (Mac 78) (ABC-
immunoperoxidase, original magnification x 250).
of the antibodies, except MMP3, for which one tumour
stained moderately. The pattern of staining in low bile duct
tumours was similar to that in adenocarcinomas of the
pancreas and ampulla.
All of the chronic pancreatitis sections showed immuno
reactivity in acinar and ductal epithelial components with
each antibody, which for MMP2 and MMP3 was at least
moderately strong in three out of five, whereas for TIMPI
the epithelial staining was significant in only one out of five.
The immunoreactivity in the malignant epithelium was
high with all of the antibodies in both adenocarcinomas of
pancreas and ampulla (GL22 100% of pancreatic cases vs
100% of ampullary cases, GL8 100% vs 100%, Mac78 93%
vs 92% and Maci5 93% vs 100%). In the malignant stromal
tissue the immunoreactivity was much less (GL22 37% of
pancreatic cases vs 17% of ampullary cases, GL8 40% vs
100%, Mac78 15% vs 34%, MaciS 4% vs 17%) and in
normal tissue away from the malignant areas the immuno
reactivity was even lower (GL22 15% of pancreatic cases vs
0% of ampullary cases, GL8 0% vs 0%, Mac78 4% vs 16%,
MaciS 4% vs 33%) (Tables II and III).
With each antibody the epithelial cell staining was
significantly stronger than either stromal or normal cell
staining in both adenocarcinomas of the pancreas
(P<0.0001) and ampulla (P<0.003) and with each antibody
there was a significant trend for epithelial cells to have
moderate to strong staining, stromal cells to have moderate
to weak staining and normal tissue to be negative
(P<0.0001).
There was strong correlation between the immunoreactiv-
ity of the two MMP2 antibodies (P<0.0001) and between
MMP2 (GL22 or GL8) and MMP3 (P<0.0001). There was
also correlation of expression between MMP2 (GL22 or
GL8) and TIMPI (P<0.0001) and between MMP3 and
TIMPI (P<0.0001), but this was only significant when the
data were considered as two groups, negative compared with
any level of immunoreactivity. The generally low levels of
immunoreactivity of TIMPI in the cancers and the small
proportion of cases showing significant immunoreactivity
justify this consideration.
Immunoreactivity for TIMP1 was absent or weak in 15
out of 16 cases of pancreatic cancer and four out of eight
cases of ampullary cancer with lymph node metastases
compared with eight out of 11 and one out of four cases
respectively without lymph node metastases (P<0.02) (Table
IV). There was increased immunoreactivity for MMP2 (GL8)
with increasing tumour grade (P<0.01) (Table V).
There was no correlation or trend between lymph node
stage or tumour differentiation and any of the other
antibodies, nor between tumour stage and tumour size and
any of the antibodies.MMP2,3 and TIMPI expression in pancreatic disease
SR Bramhall et al
Figure 3 A well-differentiated ductal adenocarcinoma showing
moderately intense cytoplasmic and apical membrane staining for
MMP2 (GL22). Note the negative benign glands from the
ampullary region (ABC-immunoperoxidase, original magnifica-
tion x 250).
Discussion
This study has shown the reactivity of the two antibodies
recognising MMP2 significantly correlated, reflecting their
specificity. The immunoreactivity of MMP2 and MMP3 also
correlated and this was perhaps surprising, as these two
enzymes have different substrate specificities (Cottam and
Rees, 1993) and appear to be important in different diseases.
MMP3 plays a role in the activation of other members of the
MMP family (Murphy et al., 1987; Ito and Nagase, 1988)
although not in the case of MMP2 where MT-MMP is a
likely candidate (Sato et al., 1994).
The antibodies to MMP2 (GL8 and GL22) both recognise
pro-MMP2 and active MMP2 in solution phase, but in fixed
tissues show a different reactivity pattern. GL22 demonstrates
membrane and/or cytoplasmic staining which is polarised to
the apex in differentiated cells, and rarely staining stromal
cells while GL8 shows a cytoplasmic reactivity pattern in
epithelial and stromal cells similar to other MMP2 antibodies
that we have previously described (Poulsom et al., 1992).
MMP2 has been shown to be produced by the RWP-1
human pancreatic cancer cell line (Zucker et al., 1990).
Plasma membrane fractions of the cell line were prepared by
differential centrifugation and the membrane fraction
extracted with N-butanol. Gelatin zymography showed
proteinase bands of 92, 70 and 62 kDa and immunoblotting
resulted in recognition of the 70 kDa protein but not the
92 kDa (Zucker et al., 1990). It has been suggested that it is
the membrane localisation of the MMP2 in the pancreatic
cancer cells that is critical rather than the species of type IV
collagenase (Zucker et al., 1992). Certain human cancers have
been shown to express MMP2, including adenocarcinoma of
Figure 4 The same tumour as Figure 2, showing moderately
strong cytoplasmic staining for TIMPI (Mac 15) (ABC-
immunoperoxidase, original magnification x250).
Figure 5 A poorly differentiated ampullary adenocarcinoma
showing strong staining for MMP2 (GL8), maximal in
pleomorphic single invasive cells rather than neoplastic glands
(ABC-immunoperoxidase, original magnification x 100).
the colon, in which 10 out of 12 expressed the transcript for
MMP2 but in desmoplastic fibroblasts rather than neoplastic
cells. The same phenomenon was found in breast, skin and
ovarian carcinomas (Poulsom et al., 1992, 1993; Naylor et al.,
1994). The role of MMP3 in human adenocarcinoma is not
well documented, although it appears to be important in the
progression of squamous cell carcinomas (Ostrowski et al.,
1988).
While immunoreactivities of both MMP2 and MMP32,3 md TI
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Fiure 6 Low-power view showing strong staining for MMP2 in
poorly differentiated invasive ampullary adenocarcinoma cells,
contrasting with the entrapped benign glands (ABC-inunmunoper-
oxidase, original magnification x250).
(Figures I and 2) locahised to the cytoplasm of the malignant
epithelial cels in this series of pancreatic diseases, in many
sections MMP2 (Figure 3) had large amounts of cellular
membrane reactivity with the GL22 antibody especially at the
invasion front. MMP2 appears to be produced in the stromal
cels but activated and therefore locai-sed by immunohisto-
chemistry to the epithelal cels (Poulsom et at., 1992). The
recent finding by Sato et al. (1994) of a new member of the
matrix metalloproteinases which is membrane-bound (MT-
MMP) and activates pro-MMP2 may help to explain these
findings. There is no evidence that MMP3 is produced by
stromal cells in the same way that MMP2 is, and this is
confirmed by our findings of mainly cytoplasmic reactivity
with this antibody. Although the specific inhibitor for MMP2
is TIMP2 (Stetler-Stevenson et al., 1990), TalMI will also
bind MMP2 and elevated expression of TIMPI transcripts
was found in all five colorectal cancers examined in a recent
series (Stetler-Stevenson et al., 1990). TIMPI may be
localised at the sites where MMP2 is active and this is
supported by finding correlation of immunoreactivity for
MMP2 and TIMPI (Figures 3 and 4). The immunoreactivity
of MMP3 and TIMPI also correlated, in keeping with
previous studies (Wilhelm et al., 1989).
It has been shown previously in human pancreatic cancer
cells that expression of MMP1 correlated with spontaneous
metastatic ability (Taniguchi et al., 1992). An increase in type
I collagenolytic activity was noted in a subclone of the
human pancreatic cancer cell line SUIT2 that demonstrated
an increased metastasising ability in nude mice (Taniguchi et
al., 1992). Reduced expression of TIMP is known to be
associated with tumour cell line progression (Khokka et al.,
1991) but evidence for this in human tumours has been
lacking. A putative reduction in TIMPl expression in
patients with lymph node metastasis from other cancer
types has not been previously described. During the
progression of tumours the check on proteolytic activity
afforded by the specific enzyme inhibitors may be reduced,
which allows a relatively greater proteolytic activity of
MMP2 or other metalloproteinases (Liotta and Stetler-
Stevenson, 1991). The inverse relationship between tumour
differentiation and expression of MMP2 provides further
evidence of a central role for this enzyme in pancreatic and
ampullary tumour progression.
These data strongly implicate MMP2, MMP3 and TIMPI
in pancreatic and ampullary carcinoma progression. MMP2
immunoreactivity was directly related to tumour dediffer-
entiation (Figures 5 and 6) and invasive potential and
reduced expression of its specific inhibitor (TIMPI) may be
involved with increased metastatic ability. Although adeno-
carcinomas of the pancreas and ampulla of Vater show
distinct differences in clinical outcome the present study
supports the notion that these differences may be related to
the stage of clinical presentation or biological characteristics
other than the expression of MMP2, MMP3 and TIMPl.
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